Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2008 Results
Date:10/30/2008

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $899,035 $2,988,069

Accrued expenses 3,082,442 9,789,738

Total current liabilities 3,981,477 12,777,807

Long-term liabilities:

Deferred rent 496,774 354,042

Total liabilities 4,478,251 13,131,849

Stockholders' equity:

Common stock 26,653 26,653

Additional paid-in capital 270,279,679 257,600,368

Accumulated other comprehensive

income (loss) (241,814) 12,176

Deficit accumulated during the

development stage (217,470,488) (173,910,266)

Total stockholders' equity 52,594,030 83,728,931

Total liabilities and

stockholders' equity $57,072,281 $96,860,780

VANDA PHARMACEUTICALS INC.

(A Development Stage Enterprise)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

Nine Months Ended

September 30, September 30,

2008 2007

Cash flows from operating activities:

Net loss $(43,560,222) $(53,321,284)

Adjustments to reconcile net income

to net cash used in operating

activities:

Depreciation and amortization 403,141 446,806

Stock-based compensation 12,679,311 14,480,108

Loss on disposal of assets (173) 2
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... Kingdom -based Lab M Holdings, a developer, manufacturer ... Lab M was founded in 1971, ... testing and diagnostic products for the global food, water, ... into more than 70 countries worldwide, and has several ...
(Date:8/27/2015)... -- The National Necrotizing Fasciitis Foundation (NNFF) ... doctors at Vanderbilt University Hospital in Nashville, ... Dr. John Crew , director of the ... in Daly City, CA. ... by Dr. Crew, that had previously saved the lives ...
(Date:8/27/2015)... GUELPH, ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. ... the three and six-month periods ended June 30, 2015. Biorem,s complete ... ( www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per ... , 2014 , 2015 , ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... August 27, 2015 GlassesOff (OTCBB: GLSO), ... functions in the human vision system, announced today a partnership ... guard Chris Paul to develop a new mobile ... to improve their real-life on-court performance. Vision is ... it is shooting a ball or blocking a pass. The ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... 3 The Connecticut Technology,Council and UHY LLP is ... Connecticut. The list of winning companies, called the UHY ... revenue growth over the last four,years. Companies considered for ... of the public companies winning this year exceeding,$1Billion in ...
... MS, EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that the ... U.S. pivotal phase III MAESTRO-03 trial of dirucotide ... a safety analysis,and recommended that the trial continue ...
... for Ap3ana, CTI,s ,personalized medicine, venture, SEATTLE, ... CTIC ) announced today that Christina A. Waters, ... Tyr Pharma and formerly Director of,Scientific Development at ... named President of CTI Europe. Based in Bresso, ...
Cached Biology Technology:Connecticut Technology Council Announces UHY LLP Tech Top 40 Winners 2BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4
(Date:8/12/2015)... Aug. 12, 2015  New research unveiled at ... Android phones to steal users, fingerprints. Information released ... of fingerprint scanners on mobile devices, making the ... secure biometrics on mobile devices, HYPR Corp. recently ... convenient authentication systems with strong cryptographic security. More ...
(Date:8/10/2015)... BOSTON and TELTOW, Germany ... SensoMotoric Instruments (SMI), a world leader in Eye ... the completion of its OEM Eye Tracking Platform for ... Eye Tracking Platform contains reference designs for seamless integration ... kiosk systems, virtual reality HMDs and augmented reality smart ...
(Date:8/6/2015)... and TELTOW, Germany , August ... Siggraph Conference, SensoMotoric Instruments (SMI) shows the ... , based on Epson,s Moverio BT-200 see-through ... platform. With this new solution, unprecedented quality and efficiency ... interaction with context-sensitive displays. For the first time, professionals ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... promising on paper; things are,often very different in reality. ... are supposed to strip the "immortal" (able to,divide indefinitely) ... to block their function, preventing them to inhibit completely,the ... for something,else? Hell no! Look out for whats stopping ...
... Notch pathway ,is an important molecular signaling mechanism whose ... nearly a century since the,identification of a mutant strain ... lab in 1910. Later studies,revealed that the Notch gene ... the cell membrane and which is capable of,interacting with ...
Cached Biology News:GATA: a graphic alignment tool for comparative sequence analysis 2Combination therapy boosts effectiveness of telomere-directed cancer cell death 2Bound for destruction: Ubiquitination protects against improper Notch signaling 2Bound for destruction: Ubiquitination protects against improper Notch signaling 3
... intended for laboratory research use only. ... buffered formalin and embedded in paraffin. ... certified pathologists. Tissue cores were removed ... a new recipient paraffin block, in an ...
Metamine is an autonomous data mining tool that extends the capabilities of conventional research teams. It is a proactive agent that searches for significant results buried within the GeNet data rep...
... X-Ray System from KUBTEC is a dual capability ... three dimensional representation of the specimen under test. ... specimen X-ray images, the micro focus source also ... detail in standard 2D images. The 50 mm ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
Biology Products: